Cargando…
Clinical relevance of single item quality of life indicators in cancer clinical trials
We investigated the hypothesis that global single-item quality-of-life indicators are less precise for specific treatment effects (discriminant validity) than multi-item scales but similarly efficient for overall treatment comparisons and changes over time (responsiveness) because they reflect the s...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363885/ https://www.ncbi.nlm.nih.gov/pubmed/11336464 http://dx.doi.org/10.1054/bjoc.2001.1785 |
_version_ | 1782153816001478656 |
---|---|
author | Bernhard, J Sullivan, M Hürny, C Coates, A S Rudenstam, C-M |
author_facet | Bernhard, J Sullivan, M Hürny, C Coates, A S Rudenstam, C-M |
author_sort | Bernhard, J |
collection | PubMed |
description | We investigated the hypothesis that global single-item quality-of-life indicators are less precise for specific treatment effects (discriminant validity) than multi-item scales but similarly efficient for overall treatment comparisons and changes over time (responsiveness) because they reflect the summation of the individual meaning and importance of various factors. Linear analogue self-assessment (LASA) indicators for physical well-being, mood and coping were compared with the Hospital Anxiety and Depression Scale (HAD), the Mood Adjective Check List (MACL) and the emotional behaviour and social interaction scales of the Sickness Impact Profile (SIP) in 84 patients with early breast cancer receiving adjuvant therapy. Discriminant validity was investigated by multitrait-multimethod correlation, responsiveness by standardized response mean (SRM). Discriminant validity of the indicators was present at baseline but less under treatment. Responsiveness was demonstrated by the expected pattern among treatments (P = 0.008). In patients without chemotherapy, the SRMs indicated moderate (0.5–0.8) to large (>0.8) improvements in physical well-being (0.70), coping (0.92), HAD anxiety (0.89) and depression (1.19), and MACL mental well-being (0.68). In patients with chemotherapy for the first 3 months, small but clinically significant improvements (>).2) included mood (0.38), coping (0.41), HAD axiety (0.31) and MACL mental well-being (0.35). Patients with 6 months chemotherapy showed no changes. The indicators also reflected mood disorders (HAD) and marked psychosocial dysfunction (SIP) at baseline and under treatment according to pre-defined cut-off levels. Global indicators were confirmed to be efficient for evaluating treatments overall and changes over time. The lower reliability of single as opposed to multi-item scales affects primarily their discriminant validity. This is less decisive in large sample sizes. © 2001 Cancer Research Campaign http://www.bjcancer.com |
format | Text |
id | pubmed-2363885 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23638852009-09-10 Clinical relevance of single item quality of life indicators in cancer clinical trials Bernhard, J Sullivan, M Hürny, C Coates, A S Rudenstam, C-M Br J Cancer Regular Article We investigated the hypothesis that global single-item quality-of-life indicators are less precise for specific treatment effects (discriminant validity) than multi-item scales but similarly efficient for overall treatment comparisons and changes over time (responsiveness) because they reflect the summation of the individual meaning and importance of various factors. Linear analogue self-assessment (LASA) indicators for physical well-being, mood and coping were compared with the Hospital Anxiety and Depression Scale (HAD), the Mood Adjective Check List (MACL) and the emotional behaviour and social interaction scales of the Sickness Impact Profile (SIP) in 84 patients with early breast cancer receiving adjuvant therapy. Discriminant validity was investigated by multitrait-multimethod correlation, responsiveness by standardized response mean (SRM). Discriminant validity of the indicators was present at baseline but less under treatment. Responsiveness was demonstrated by the expected pattern among treatments (P = 0.008). In patients without chemotherapy, the SRMs indicated moderate (0.5–0.8) to large (>0.8) improvements in physical well-being (0.70), coping (0.92), HAD anxiety (0.89) and depression (1.19), and MACL mental well-being (0.68). In patients with chemotherapy for the first 3 months, small but clinically significant improvements (>).2) included mood (0.38), coping (0.41), HAD axiety (0.31) and MACL mental well-being (0.35). Patients with 6 months chemotherapy showed no changes. The indicators also reflected mood disorders (HAD) and marked psychosocial dysfunction (SIP) at baseline and under treatment according to pre-defined cut-off levels. Global indicators were confirmed to be efficient for evaluating treatments overall and changes over time. The lower reliability of single as opposed to multi-item scales affects primarily their discriminant validity. This is less decisive in large sample sizes. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-05 /pmc/articles/PMC2363885/ /pubmed/11336464 http://dx.doi.org/10.1054/bjoc.2001.1785 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Bernhard, J Sullivan, M Hürny, C Coates, A S Rudenstam, C-M Clinical relevance of single item quality of life indicators in cancer clinical trials |
title | Clinical relevance of single item quality of life indicators in cancer clinical trials |
title_full | Clinical relevance of single item quality of life indicators in cancer clinical trials |
title_fullStr | Clinical relevance of single item quality of life indicators in cancer clinical trials |
title_full_unstemmed | Clinical relevance of single item quality of life indicators in cancer clinical trials |
title_short | Clinical relevance of single item quality of life indicators in cancer clinical trials |
title_sort | clinical relevance of single item quality of life indicators in cancer clinical trials |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363885/ https://www.ncbi.nlm.nih.gov/pubmed/11336464 http://dx.doi.org/10.1054/bjoc.2001.1785 |
work_keys_str_mv | AT bernhardj clinicalrelevanceofsingleitemqualityoflifeindicatorsincancerclinicaltrials AT sullivanm clinicalrelevanceofsingleitemqualityoflifeindicatorsincancerclinicaltrials AT hurnyc clinicalrelevanceofsingleitemqualityoflifeindicatorsincancerclinicaltrials AT coatesas clinicalrelevanceofsingleitemqualityoflifeindicatorsincancerclinicaltrials AT rudenstamcm clinicalrelevanceofsingleitemqualityoflifeindicatorsincancerclinicaltrials |